

# ANGPT1 Antibody (CT)

**ALTERNATE NAMES:** ANGPT1; KIAA0003; Angiotensin-1

**CATALOG #:** 6760-100

**AMOUNT:** 100 µl

**HOST/ISOTYPE:** Rabbit IgG

**IMMUNOGEN:** This ANGPT1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 374-402 amino acids from the C-terminal region of human ANGPT1.

**PURIFICATION:** This antibody is purified through a protein A column, followed by peptide affinity purification.

**MOLECULAR WEIGHT:** ~57.51 kDa

**FORM:** Liquid


**FORMULATION:** Supplied in PBS with 0.09% (W/V) sodium azide.

**SPECIES REACTIVITY:** Human. Predicted cross reactivity with mouse, bovine and pig samples.

**STORAGE CONDITIONS:** Maintain refrigerated at 2-8°C for up to 6 months. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.

**DESCRIPTION:** Angiotensin-1 (Ang-1) is a secreted ligand for Tie-2, a tyrosine-kinase receptor expressed primarily on vascular endothelial cells and early hematopoietic cells. Ang-1/ Tie-2 signaling promotes angiogenesis during the development, remodeling, and repair of the vascular system. Transgenic mice lacking expression of either Ang-1 or Tie-2 fail to develop a fully functional cardiovascular system and die before birth. Postnatally, the angiogenic activity of Ang-1/Tie-2 is required during normal tissue repair and remodeling of the female endometrium in the menstrual cycle. Ang-1/Tie-2 signaling appears to be regulated by Angiotensin-2 (Ang-2), a natural antagonist for Tie-2 that exerts its effects through an internal autocrine loop mechanism. In addition to suppressing endothelial cell activation by inhibiting the expression of adhesion and inflammatory molecules, Ang-1 enhances endothelial cell survival and capillary morphogenesis, and lessens capillary permeability. As such, Ang-1 has a potential to become an effective therapeutic agent for treating various endothelium disorders, including several severe human pulmonary diseases. The efficacy of cell-based Ang-1 gene therapy for acute lung injury (ALI) has recently been studied in a rat model of ALI. The results of this study show that such therapy can markedly improve lung condition and suggest that Ang-1 therapy may represent a potential new strategy for the treatment and/or prevention of acute respiratory distress injury (ARDI), a significant cause of morbidity and mortality in critically ill patients. Recombinant human ANG-1, derived from HeLa cells, is a C-terminal histidine tagged glycoprotein which migrates with an apparent molecular mass of 60.0 – 70.0 kDa by SDS-PAGE under reducing conditions. Sequencing analysis shows N-terminal sequences starting with Ser-20 and with Asp-70 of the 498 amino acid precursor protein.

**APPLICATION:** Western blot: ~1:1000.



Western blot analysis of NCI-H292 cell line lysate. (35 µg protein).

**RELATED PRODUCTS:**

- ANG-1, human recombinant (Cat. No. 7115-10, -50)
- Human CellExp™ Angiotensin-2, human recombinant (Cat. No. 7395-10, -50)
- Angiotensin-2, mouse recombinant (Cat. No. 7555-10)
- ANG-2, human recombinant (Cat. No. 7116-10, -50)
- ANGPTL3 (human) Serum ELISA Kit (Cat. No. K4914-100)
- ANGPTL3 (mouse/rat) Serum ELISA Kit (Cat. No. K4915-100)
- ANGPTL6 (human) Serum ELISA Kit (Cat. No. K4916-100)
- Angiotensin-1 (human) ELISA Kit (Cat. No. K7115-100)
- Angiotensin-2 (human) ELISA Kit (Cat. No. K7116-100)

**Note:** This information is only intended as a guide. The optimal dilutions must be determined by the user.

**FOR RESEARCH USE ONLY! Not to be used on humans.**